Here are the DEF 14A proxy statements from NextCure, Inc. (NXTC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow NXTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXTC filings page.
NextCure, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 18, 2026 at 11:00 a.m. Eastern Time. Holders of 3,607,555 common shares as of April 22, 2026 can participate and vote online.
Stockholders are asked to elect two Class I directors, Anne Borgman, M.D., and John G. Houston, Ph.D., to terms ending in 2029, ratify Ernst & Young LLP as independent auditor for 2026, and approve an advisory “Say‑on‑Pay” vote on executive compensation. They are also asked to approve an amended and restated 2019 Omnibus Incentive Plan that increases shares of common stock authorized for equity awards.
The proxy highlights NextCure’s focus as a clinical‑stage cancer biotech developing antibody‑drug conjugates and other biologics, including SIM0505 and LNCB74, with Phase 1 data updates expected in 2026. It also details board structure, director pay, and 2025 compensation for key executives.